Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Economic evaluation of pharmacogenomic-guided warfarin treatment for elderly Croatian atrial fibrillation patients with ischemic stroke.

Pharmacogenomics - 1 Jan 2015

Mitropoulou Christina, Fragoulakis Vasilios, Bozina Nada, Vozikis Athanassios, Supe Svjetlana, Bozina Tamara, Poljakovic Zdravka, van Schaik Ron H, Patrinos George P

Abstract excerpt

BACKGROUND & METHODS: Economic evaluation in genomic medicine is an emerging discipline to assess the cost-effectiveness of genome-guided treatment. Here, we developed a pharmaco-economic model to assess whether pharmacogenomic (PGx)-guided warfarin treatment of elderly ischemic stroke patients with atrial fibrillation in Croatia is cost effective compared with non-PGx therapy. The time horizon of the model was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticoagulants
Share to Atrial Fibrillation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cost-Benefit Analysis

Share to Croatia

Share to Drug Costs

Share to Health Care Costs

Share to Quality-Adjusted Life Years

Share to Warfarin

Source

Identifiers

PMID: 25616100
DOI: 10.2217/pgs.14.167

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Economic evaluation of pharmacogenomic-guided warfarin treatment for elderly Croatian atrial fibrillation patients with ischemic stroke.PMID 25616100Read ↗

Pharmacogenetic-guided selection of warfarin versus novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: a cost-effectiveness analysis.Semantic proximity Read ↗

Cost-effectiveness of genotype-guided warfarin therapy for anticoagulation in elderly patients with atrial fibrillation.Semantic proximity Read ↗

Pharmacoeconomic evaluation of warfarin pharmacogenomics.Semantic proximity Read ↗

Universal versus genotype-guided use of direct oral anticoagulants in atrial fibrillation patients: a decision analysis.Semantic proximity Read ↗

Economic evaluations of pharmacogenetic and genomic screening programs: update of the literature.Semantic proximity Read ↗

Genetic risk for atrial fibrillation could motivate patient adherence to warfarin therapy: a cost effectiveness analysis.Semantic proximity Read ↗

The potential clinical and economic outcomes of pharmacogenetics-oriented management of warfarin therapy - a decision analysis.Semantic proximity Read ↗

Cost-effectiveness of CYP2C19-guided antiplatelet therapy for acute coronary syndromes in Singapore.Semantic proximity Read ↗

Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation.Semantic proximity Read ↗

Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet?Semantic proximity Read ↗

Short- and long-term cost-effectiveness analysis of CYP2C19 genotype-guided therapy, universal clopidogrel, versus universal ticagrelor in post-percutaneous coronary intervention patients in Qatar.Semantic proximity Read ↗

Development of a point-of-care genetic test for effective treatment of ischaemic stroke: an early model-based cost-effectiveness analysisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.